We're delighted that the ProVascTec campaign has now reached its target and is #overfunding.
It's open until midnight on Wednesday if anyone is still interested in investing in this very exciting #Cork-based medtech company.
- An outstanding, multi-PhD Founding Team
- A cell therapy spin-out from UCC
- Patent-protected technology (already granted in Europe and the USA)
- Global market size of €14 billion
- An Enterprise Ireland High Potential Start-Up company
- Already received €100,000 from NLC Health Ventures (a Dutch-based venture capital firm)
- Qualifies for a 50% EIIS Tax Refund for private investors
- A pre-money Valuation of €5.3m
- NLC Health Ventures investing again in this round on the exact same terms as private investors
- Potential for 30x return on your investment
Visit here to invest: https://lnkd.in/gaAwPpiH
At ProVascTec we have reached an important milestone. Over the weekend we met our funding target! A special thanks to Spark Crowdfunding, who hosted our project and helped us communicating our value proposition to investors. We are excited that now can turn our plans into action, accelerating our development of a novel solution for patients suffering from critical limb ischemia, CLI.
#targetedcelltherapy, #criticallimbischemia, #peripheralvasculardiseases
